Publikationen der Medizinischen Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie CVK

Sie befinden sich hier:

Publikationen 2019

1. Döhner H., Müller-Tidow C., Lübbert M., Fiedler W., Krämer A., Westermann J., Bug G., Schlenk R.F., Krug U., Goeldner R.G., Hilbert J., Taube T. & Ottmann O.G.
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
Brit J Haematol. 2019;185(3):583-587.
 
2. Roos-Weil D., Decaudin C., Armand M., Della-Valle V., Diop M.K., Ghamlouch H., Ropars V., Hérate C., Lara D., Durot E., Haddad R., Mylonas E., Damm F., Pflumio F., Stoilova B., Metzner M., Elemento O., Dessen P., Camara-Clayette V., Cosset F.L., Verhoeyen E., Leblond V., Ribrag V., Cornillet-Lefebvre P., Rameau P., Azar N., Charlotte F., Morel P., Charbonnier J.B., Vyas P., Mercher T., Aoufouchi S., Droin N., Guillouf C., Nguyen-Khac F. & Bernard O.A.
A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.
Cancer Discov. 2019;9(6):796-811.
 
3. Jutzi J.S., Basu T., Pellmann M., Kaiser S., Steinemann D., Sanders M.A., Hinai A.S.A., Zeilemaker A., Bojtine Kovacs S., Koellerer C., Ostendorp J., Aumann K., Wang W., Raffoux E., Cassinat B., Bullinger L., Schlegelberger B., Valk P.J.M. & Pahl H.L.
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Blood. 2019;133(16):1766-1777.
 
4. Ihlow J., Gross S., Sick A., Schneider T., Flörcken A., Burmeister T., Türkmen S., Arnold R., Dörken B. & Westermann J.
AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
Leukemia Lymphoma. 2019;60(1):69-77.
 
5. Böhm M.J., Marienfeld R., Jäger D., Mellert K., von Witzleben A., Brüderlein S., Wittau M., von Baer A., Schultheiss M., Mayer-Steinacker R., Rücker F.G., Möller P., Bullinger L. & Barth T.F.E.
Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib.
Sarcoma. 2019;2019:3914232.
 
6. Simonetti G., Padella A., do Valle I.F., Fontana M.C., Fonzi E., Bruno S., Baldazzi C., Guadagnuolo V., Manfrini M., Ferrari A., Paolini S., Papayannidis C., Marconi G., Franchini E., Zuffa E., Laginestra M.A., Zanotti F., Astolfi A., Iacobucci I., Bernardi S., Sazzini M., Ficarra E., Hernandez J.M., Vandenberghe P., Cools J., Bullinger L., Ottaviani E., Testoni N., Cavo M., Haferlach T., Castellani G., Remondini D. & Martinelli G.
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Cancer-Am Cancer Soc. 2019;125(5):712-725.
 
7. Kretschmann S., Herda S., Bruns H., Russ J., van der Meijden E.D., Schlötzer-Schrehardt U., Griffioen M., Na I.K., Mackensen A. & Kremer A.N.
Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY.
J Clin Invest. 2019;130:2952-2963.
 
8. Moiseev I.S., Tsvetkova T., Aljurf M., Alnounou R.M., Bogardt J., Chalandon Y., Drokov M.Y., Dvirnyk V., Faraci M., Friis L.S., Giglio F., Greinix H.T., Kornblit B.T., Koelper C., Koenecke C., Lewandowski K., Niederwieser D., Passweg J.R., Peczynski C., Penack O., Peric Z., Piekarska A., Ronchi P.E., Rovo A., Rzepecki P., Scuderi F., Sigrist D., Siitonen S.M., Stoelzel F., Sulek K., Tsakiris D.A., Wilkowojska U., Duarte R.F., Ruutu T. & Basak G.W.
Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT.
Bone Marrow Transpl. 2019;54(7):1022-1028.
 
9. Cocciardi S., Dolnik A., Kapp-Schwoerer S., Rücker F.G., Lux S., Blätte T.J., Skambraks S., Krönke J., Heidel F.H., Schnöder T.M., Corbacioglu A., Gaidzik V.I., Paschka P., Teleanu V., Göhring G., Thol F., Heuser M., Ganser A., Weber D., Sträng E., Kestler H.A., Döhner H., Bullinger L. & Döhner K.
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Nat Commun. 2019;10(1):2031.
 
10. Basheer F., Giotopoulos G., Meduri E., Yun H., Mazan M., Sasca D., Gallipoli P., Marando L., Gozdecka M., Asby R., Sheppard O., Dudek M., Bullinger L., Döhner H., Dillon R., Freeman S., Ottmann O., Burnett A., Russell N., Papaemmanuil E., Hills R., Campbell P., Vassiliou G.S. & Huntly B.J.P.
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
J Exp Med. 2019;216(4):966-981.
 
11. Inamoto Y., Petriček I., Burns L., Chhabra S., DeFilipp Z., Hematti P., Rovó A., Schears R., Shah A., Agrawal V., Al-Khinji A., Ahmed I., Ali A., Aljurf M., Alkhateeb H., Beitinjaneh A., Bhatt N., Buchbinder D., Byrne M., Callander N., Fahnehjelm K., Farhadfar N., Gale R.P., Ganguly S., Hildebrandt G.C., Horn E., Jakubowski A., Kamble R.T., Law J., Lee C., Nathan S., Penack O., Pingali R., Prasad P., Pulanic D., Rotz S., Shreenivas A., Steinberg A., Tabbara K., Tichelli A., Wirk B., Yared J., Basak G.W., Battiwalla M., Duarte R., Savani B.N., Flowers M.E.D., Shaw B.E. & Valdés-Sanz N.
Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone Marrow Transpl. 2019;54(5):782-783.
 
12. Na I.K., Buckland M., Agostini C., Edgar J.D.M., Friman V., Michallet M., Sánchez-Ramón S., Scheibenbogen C. & Quinti I.
Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Eur J Haematol. 2019;102(6):447-456.
 
13. Kaebisch E.M., Cho M.Y., Oh Y.S., Olfe L.I., Szyska M., Becker S.C., Reinke P., Volk H.D., Gillissen B., Bullinger L., Thiel A. & Na I.K.
Cytotoxic Effects of Rabbit Anti-Thymocyte Globulin preparations on Primary Human Thymic Epithelial Cells.
Transplantation. 2019;x:x-y.
 
14. Zhao X., Zhang K., Daniel P., Wisbrun N., Fuchs H. & Fan H.
Delayed allogeneic skin graft rejection in CD26-deficient mice.
Cell Mol Immunol. 2019;16(6):557-567.
 
15. Christen F., Hoyer K., Yoshida K., Hou H.A., Waldhueter N., Heuser M., Hills R.K., Chan W., Hablesreiter R., Blau O., Ochi Y., Klement P., Chou W.C., Blau I.W., Tang J.L., Zemojtel T., Shiraishi Y., Shiozawa Y., Thol F., Ganser A., Löwenberg B., Linch D.C., Bullinger L., Valk P.J.M., Tien H.F., Gale R.E., Ogawa S. & Damm F.
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Blood. 2019;133(10):1140-1151.
 
16. Bullinger L.
IDH2 inhibition: another piece to the puzzle.
Blood. 2019;133(7):625-626.
 
17. Seika P., Klein F., Pelzer U., Pratschke J., Bahra M. & Malinka T.
Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy.
Hepatobil Surg Nutr. 2019;8(3):201-210.
 
18. Schroeder M.P., Bastian L., Eckert C., Gökbuget N., James A.R., Tanchez J.O., Schlee C., Isaakidis K., Häupl B., Baum K., Migueles Lozano O.A., Kouidri K., Pan K.T., Urlaub H., Schwartz S., Burmeister T., von Stackelberg A., Hoelzer D., Pfeiffer H., Rieger M.A., Göllner S., Oellerich T., Horstman M., Schrappe M., Wolf J., Kirschner-Schwabe R., Brüggemann M., Müller-Tidow C., Serve H., Neumann M. & Baldus C.D.
Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.
Sci Rep. 2019;9(1):4188.
 
19. Heimann S.M., Penack O., Heinz W.J., Rachow T., Egerer G., Kessel J., Claßen A.Y. & Vehreschild J.J.
Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Int J Infect Dis. 2019;83:130-138.
 
20. Pelzer U. & Sinn M.
Ist nicht obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms
Onkologe. 2019;25(8):658-660.
 
21. Penter L., Dietze K., Ritter J., Lammoglia Cobo M.F., Garmshausen J., Aigner F., Bullinger L., Hackstein H., Wienzek-Lischka S., Blankenstein T., Hummel M., Dornmair K. & Hansmann L.
Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.
Oncoimmunology. 2019;8(6):e1586409.
 
22. Herrlinger U., Tzaridis T., Mack F., Steinbach J.P., Schlegel U., Sabel M., Hau P., Kortmann R.D., Krex D., Grauer O., Goldbrunner R., Schnell O., Bähr O., Uhl M., Seidel C., Tabatabai G., Kowalski T., Ringel F., Schmidt-Graf F., Suchorska B., Brehmer S., Weyerbrock A., Renovanz M., Bullinger L., Galldiks N., Vajkoczy P., Misch M., Vatter H., Stuplich M., Schäfer N., Kebir S., Weller J., Schaub C., Stummer W., Tonn J.C., Simon M., Keil V.C., Nelles M., Urbach H., Coenen M., Wick W., Weller M., Fimmers R., Schmid M., Hattingen E., Pietsch T., Coch C., Glas M. & Neurooncology Working Group of the German Cancer Society
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet. 2019;393(10172):678-688.
 
23. James A.R., Schroeder M.P., Neumann M., Bastian L., Eckert C., Gökbuget N., Tanchez J.O., Schlee C., Isaakidis K., Schwartz S., Burmeister T., von Stackelberg A., Rieger M.A., Göllner S., Horstman M., Schrappe M., Kirschner-Schwabe R., Brüggemann M., Müller-Tidow C., Serve H., Akalin A. & Baldus C.D.
Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.
J Hematol Oncol. 2019;12(1):8.
 
24. Kochanek M., Schalk E., von Bergwelt-Baildon M., Beutel G., Buchheidt D., Hentrich M., Henze L., Kiehl M., Liebregts T., von Lilienfeld-Toal M., Classen A., Mellinghoff S., Penack O., Piepel C. & Böll B.
Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
Ann Hematol. 2019;98(5):1051-1069.
 
25. Schlenk R.F., Weber D., Fiedler W., Salih H.R., Wulf G., Salwender H., Schroeder T., Kindler T., Lübbert M., Wolf D., Westermann J., Kraemer D., Götze K.S., Horst H.A., Krauter J., Girschikofsky M., Ringhoffer M., Südhoff T., Held G., Derigs H.G., Schroers R., Greil R., Grießhammer M., Lange E., Burchardt A., Martens U., Hertenstein B., Marretta L., Heuser M., Thol F., Gaidzik V.I., Herr W., Krzykalla J., Benner A., Döhner K., Ganser A., Paschka P., Döhner H. & German-Austrian AML Study Group
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3 -ITD.
Blood. 2019;133(8):840-851.
 
26. Inamoto Y., Petriček I., Burns L., Chhabra S., DeFilipp Z., Hematti P., Rovó A., Schears R., Shah A., Agrawal V., Ahmed A., Ahmed I., Ali A., Aljurf M., Alkhateeb H., Beitinjaneh A., Bhatt N., Buchbinder D., Byrne M., Callander N., Fahnehjelm K., Farhadfar N., Gale R.P., Ganguly S., Hashmi S., Hildebrandt G.C., Horn E., Jakubowski A., Kamble R.T., Law J., Lee C., Nathan S., Penack O., Pingali R., Prasad P., Pulanic D., Rotz S., Shreenivas A., Steinberg A., Tabbara K., Tichelli A., Wirk B., Yared J., Basak G.W., Battiwalla M., Duarte R., Savani B.N., Flowers M.E.D., Shaw B.E. & Valdés-Sanz N.
Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.
Biol Blood Marrow Tr. 2019;25(5):e145-e154.
 
27. Inamoto Y., Petriček I., Burns L., Chhabra S., DeFilipp Z., Hematti P., Rovó A., Schears R., Shah A., Agrawal V., Al-Khinji A., Ahmed I., Ali A., Aljurf M., Alkhateeb H., Beitinjaneh A., Bhatt N., Buchbinder D., Byrne M., Callander N., Fahnehjelm K., Farhadfar N., Gale R.P., Ganguly S., Hildebrandt G.C., Horn E., Jakubowski A., Kamble R.T., Law J., Lee C., Nathan S., Penack O., Pingali R., Prasad P., Pulanic D., Rotz S., Shreenivas A., Steinberg A., Tabbara K., Tichelli A., Wirk B., Yared J., Basak G.W., Battiwalla M., Duarte R., Savani B.N., Flowers M.E.D., Shaw B.E. & Valdés-Sanz N.
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone Marrow Transpl. 2019;54(5):648-661.
 
28. Inamoto Y., Valdés-Sanz N., Ogawa Y., Alves M., Berchicci L., Galvin J., Greinix H., Hale G.A., Horn B., Kelly D., Liu H., Rowley S., Schoemans H., Shah A., Lupo Stanghellini M.T., Agrawal V., Ahmed I., Ali A., Bhatt N., Byrne M., Chhabra S., DeFilipp Z., Fahnehjelm K., Farhadfar N., Horn E., Lee C., Nathan S., Penack O., Prasad P., Rotz S., Rovó A., Yared J., Pavletic S., Basak G.W., Battiwalla M., Duarte R., Savani B.N., Flowers M.E.D., Shaw B.E. & Petriček I.
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Biol Blood Marrow Tr. 2019;25(2):e46-e54.
 
29. Inamoto Y., Valdés-Sanz N., Ogawa Y., Alves M., Berchicci L., Galvin J., Greinix H., Hale G.A., Horn B., Kelly D., Liu H., Rowley S., Schoemans H., Shah A., Lupo Stanghellini M.T., Agrawal V., Ahmed I., Ali A., Bhatt N., Byrne M., Chhabra S., DeFilipp Z., Fahnehjelm K., Farhadfar N., Horn E., Lee C., Nathan S., Penack O., Prasad P., Rotz S., Rovó A., Yared J., Pavletic S., Basak G.W., Battiwalla M., Duarte R., Savani B.N., Flowers M.E.D., Shaw B.E. & Petriček I.
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone Marrow Transpl. 2019;54(5):662-673.
 
30. Pelzer U., Geisel D., Striefler J., Falkenthal J. & Bahra M.
Pankreaskarzinom: Eine interdisziplinäre, multimodale Herausforderung
J Onkol. 2019;6:13-31.
 
31. Bastian L., Schroeder M.P., Eckert C., Schlee C., Tanchez J.O., Kämpf S., Wagner D.L., Schulze V., Isaakidis K., Lázaro-Navarro J., Hänzelmann S., James A.R., Ekici A., Burmeister T., Schwartz S., Schrappe M., Horstmann M., Vosberg S., Krebs S., Blum H., Hecht J., Greif P.A., Rieger M.A., Brüggemann M., Gökbuget N., Neumann M. & Baldus C.D.
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2019;33(8):1895-1909.
 
32. Wojciechowski A., Duckert M., Hartmann J., Bullinger L. & Matzdorff A.
Retroperitoneal Hematoma after Bone Marrow Biopsy: The First Cut Should Not Be the Deepest.
Oncol Res Treat. 2019;42(5):283-288.
 
33. Khorana A.A., Soff G.A., Kakkar A.K., Vadhan-Raj S., Riess H., Wun T., Streiff M.B., Garcia D.A., Liebman H.A., Belani C.P., O'Reilly E.M., Patel J.N., Yimer H.A., Wildgoose P., Burton P., Vijapurkar U., Kaul S., Eikelboom J., McBane R., Bauer K.A., Kuderer N.M., Lyman G.H. & CASSINI Investigators
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
New Engl J Med. 2019;380(8):720-728.
 
34. Frick M., Chan W., Arends C.M., Hablesreiter R., Halik A., Heuser M., Michonneau D., Blau O., Hoyer K., Christen F., Galan-Sousa J., Noerenberg D., Wais V., Stadler M., Yoshida K., Schetelig J., Schuler E., Thol F., Clappier E., Christopeit M., Ayuk F., Bornhäuser M., Blau I.W., Ogawa S., Zemojtel T., Gerbitz A., Wagner E.M., Spriewald B.M., Schrezenmeier H., Kuchenbauer F., Kobbe G., Wiesneth M., Koldehoff M., Socié G., Kroeger N., Bullinger L., Thiede C. & Damm F.
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
J Clin Oncol. 2019;37(5):375-385.
 
35. Klein F., Pelzer U., Schmuck R.B., Malinka T., Felsenstein M., Denecke T., Pratschke J. & Bahra M.
Strengths, Weaknesses, Opportunities, and Threats of Centralized Pancreatic Surgery: a Single-Center Analysis of 3000 Consecutive Pancreatic Resections.
J Gastrointest Surg. 2019;23(3):492-502.
 
36. Lee S. & Schmitt C.A.
The dynamic nature of senescence in cancer.
Nat Cell Biol. 2019;21(1):94-101.

Publikationen 2018

1. Becker S.C., Szyska M., Mensen A., Hellwig K., Otto R., Olfe L., Volk H.D., Dörner T., Dörken B., Scheibenbogen C., Schröder J., Hocke A.C. & Na I.K.
A comparative analysis of human bone marrow-resident and peripheral memory B cells.
J Allergy Clin Immun. 2018;141(5):1911-1913.e7.
 
2. Beck D., Thoms J.A.I., Palu C., Herold T., Shah A., Olivier J., Boelen L., Huang Y., Chacon D., Brown A., Babic M., Hahn C., Perugini M., Zhou X., Huntly B.J., Schwarzer A., Klusmann J.H., Berdel W.E., Wörmann B., Büchner T., Hiddemann W., Bohlander S.K., To L.B., Scott H.S., Lewis I.D., D'Andrea R.J., Wong J.W.H. & Pimanda J.E.
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
Leukemia. 2018;32(2):263-272.
 
3. Szyska M., Herda S., Althoff S., Heimann A., Russ J., D'Abundo D., Dang T.M., Durieux I., Dörken B., Blankenstein T. & Na I.K.
A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells In Vivo.
Cancer Immunol Res. 2018;6(1):110-120.
 
4. Herold T., Jurinovic V., Batcha A.M.N., Bamopoulos S.A., Rothenberg-Thurley M., Ksienzyk B., Hartmann L., Greif P.A., Phillippou-Massier J., Krebs S., Blum H., Amler S., Schneider S., Konstandin N., Sauerland M.C., Görlich D., Berdel W.E., Wörmann B.J., Tischer J., Subklewe M., Bohlander S.K., Braess J., Hiddemann W., Metzeler K.H., Mansmann U. & Spiekermann K.
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Haematologica. 2018;103(3):456-465.
 
5. Paschka P., Schlenk R.F., Weber D., Benner A., Bullinger L., Heuser M., Gaidzik V.I., Thol F., Agrawal M., Teleanu V., Lübbert M., Fiedler W., Radsak M., Krauter J., Horst H.A., Greil R., Mayer K., Kündgen A., Martens U., Heil G., Salih H.R., Hertenstein B., Schwänen C., Wulf G., Lange E., Pfreundschuh M., Ringhoffer M., Girschikofsky M., Heinicke T., Kraemer D., Göhring G., Ganser A., Döhner K. & Döhner H.
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Leukemia. 2018;32(7):1621-1630.
 
6. Grünwald V., Eberhardt B., Bex A., Flörcken A., Gauler T., Derlin T., Panzica M., Dürr H.R., Grötz K.A., Giles R.H., von Falck C., Graser A., Muacevic A. & Staehler M.
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.
Nat Rev Urol. 2018;15(8):511-521.
 
7. Raffel S., Falcone M., Kneisel N., Hansson J., Wang W., Lutz C., Bullinger L., Poschet G., Nonnenmacher Y., Barnert A., Bahr C., Zeisberger P., Przybylla A., Sohn M., Tönjes M., Erez A., Adler L., Jensen P., Scholl C., Fröhling S., Cocciardi S., Wuchter P., Thiede C., Flörcken A., Westermann J., Ehninger G., Lichter P., Hiller K., Hell R., Herrmann C., Ho A.D., Krijgsveld J., Radlwimmer B. & Trumpp A.
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut -like DNA hypermethylation.
Nature. 2018;560(7718):E28.
 
8. Neuendorff N.R., Hemmati P., Arnold R., Ihlow J., Dörken B., Müller-Tidow C. & Westermann J.
BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?
Blood Adv. 2018;2(12):1409-1411.
 
9. Jeck J., Kassubek R., Coburger J., Edenhofer S., Schönsteiner S.S., Ludolph A.C., Schmitz B., Engelke J., Mayer-Steinacker R., Lewerenz J. & Bullinger L.
Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
Ther Adv Neurolog Disorder. 2018;11:1756285617753597.
 
10. Bluhm J., Kieback E., Marino S.F., Oden F., Westermann J., Chmielewski M., Abken H., Uckert W., Höpken U.E. & Rehm A.
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Mol Ther. 2018;26(8):1906-1920.
 
11. Rücker F.G., Dolnik A., Blätte T.J., Teleanu V., Ernst A., Thol F., Heuser M., Ganser A., Döhner H., Döhner K. & Bullinger L.
Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.
Haematologica. 2018;103(1):e17-e20.
 
12. Lux S. & Bullinger L.
Circular RNAs in Cancer.
Adv Exp Med Biol. 2018;1087:215-230.
 
13. Gary R., Aigner M., Moi S., Schaffer S., Gottmann A., Maas S., Zimmermann R., Zingsem J., Strobel J., Mackensen A., Mautner J., Moosmann A. & Gerbitz A.
Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.
J Transl Med. 2018;16(1):124.
 
14. Schranz K., Hubmann M., Harin E., Vosberg S., Herold T., Metzeler K.H., Rothenberg-Thurley M., Janke H., Bräundl K., Ksienzyk B., Batcha A.M.N., Schaaf S., Schneider S., Bohlander S.K., Görlich D., Berdel W.E., Wörmann B.J., Braess J., Krebs S., Hiddemann W., Mansmann U., Spiekermann K. & Greif P.A.
Clonal heterogeneity of FLT3 -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.
Oncotarget. 2018;9(53):30128-30145.
 
15. Ter Veer E., van Rijssen L.B., Besselink M.G., Mali R.M.A., Berlin J.D., Boeck S., Bonnetain F., Chau I., Conroy T., Van Cutsem E., Deplanque G., Friess H., Glimelius B., Goldstein D., Herrmann R., Labianca R., Van Laethem J.L., Macarulla T., van der Meer J.H.M., Neoptolemos J.P., Okusaka T., O'Reilly E.M., Pelzer U., Philip P.A., van der Poel M.J., Reni M., Scheithauer W., Siveke J.T., Verslype C., Busch O.R., Wilmink J.W., van Oijen M.G.H. & van Laarhoven H.W.M.
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Lancet Oncol. 2018;19(3):e151-e160.
 
16. Stehle D., Grimm M., Einsele-Scholz S., Ladwig F., Johänning J., Fischer G., Gillissen B., Schulze-Osthoff K. & Essmann F.
Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax.
Sci Rep. 2018;8(1):12434.
 
17. L'Abbate A., Tolomeo D., Cifola I., Severgnini M., Turchiano A., Augello B., Squeo G., D'Addabbo P., Traversa D., Daniele G., Lonoce A., Pafundi M., Carella M., Palumbo O., Dolnik A., Muehlematter D., Schoumans J., Van Roy N., De Bellis G., Martinelli G., Merla G., Bullinger L., Haferlach C. & Storlazzi C.T.
Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
Leukemia. 2018;32(10):2304.
 
18. Döhner H., Dolnik A., Tang L., Seymour J.F., Minden M.D., Stone R.M., Del Castillo T.B., Al-Ali H.K., Santini V., Vyas P., Beach C.L., MacBeth K.J., Skikne B.S., Songer S., Tu N., Bullinger L. & Dombret H.
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Leukemia. 2018;32(12):2546-2557.
 
19. Nagel M., Schulz J., Maderer A., Goepfert K., Gehrke N., Thomaidis T., Thuss-Patience P.C., Al-Batran S.E., Hegewisch-Becker S., Grimminger P., Galle P.R., Möhler M. & Schattenberg J.M.
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Tumor Biol. 2018;40(3):1010428318764007.
 
20. Bokemeyer C., Busse R., Engel J., Gebauer A., Hallek M., Heinemann V., Lüftner D. & Wörmann B.
Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.
Oncol Res Treat. 2018;41 Suppl 3:2-26.
 
21. Matzdorff A. & Wörmann B.
[Diagnosis and Therapy of Immune thrombocytopenia].
Deut Med Wochenschr. 2018;143(15):1076-1081.
 
22. Ruhnke M., Behre G., Buchheidt D., Christopeit M., Hamprecht A., Heinz W., Heussel C.P., Horger M., Kurzai O., Karthaus M., Löffler J., Maschmeyer G., Penack O., Rieger C., Rickerts V., Ritter J., Schmidt-Hieber M., Schuelper N., Schwartz S., Ullmann A., Vehreschild J.J., von Lilienfeld-Toal M., Weber T. & Wolf H.H.
Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).
Mycoses. 2018;61(11):796-813.
 
23. Gaidzik V.I., Weber D., Paschka P., Kaumanns A., Krieger S., Corbacioglu A., Krönke J., Kapp-Schwoerer S., Krämer D., Horst H.A., Schmidt-Wolf I., Held G., Kündgen A., Ringhoffer M., Götze K., Kindler T., Fiedler W., Wattad M., Schlenk R.F., Bullinger L., Teleanu V., Schlegelberger B., Thol F., Heuser M., Ganser A., Döhner H., Döhner K. & German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Leukemia. 2018;32(1):30-37.
 
24. Penack O. & Luft T.
Editorial: Endothelial Dysfunction During Inflammation and Alloimmunity.
Front Immunol. 2018;9:2886.
 
25. Bohl S.R., Bullinger L. & Rücker F.G.
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Expert Rev Hematol. 2018;11(5):361-371.
 
26. Mathew N.R., Baumgartner F., Braun L., O'Sullivan D., Thomas S., Waterhouse M., Müller T.A., Hanke K., Taromi S., Apostolova P., Illert A.L., Melchinger W., Duquesne S., Schmitt-Graeff A., Osswald L., Yan K.L., Weber A., Tugues S., Spath S., Pfeifer D., Follo M., Claus R., Lübbert M., Rummelt C., Bertz H., Wäsch R., Haag J., Schmidts A., Schultheiss M., Bettinger D., Thimme R., Ullrich E., Tanriver Y., Vuong G.L., Arnold R., Hemmati P., Wolf D., Ditschkowski M., Jilg C., Wilhelm K., Leiber C., Gerull S., Halter J., Lengerke C., Pabst T., Schroeder T., Kobbe G., Rösler W., Doostkam S., Meckel S., Stabla K., Metzelder S.K., Halbach S., Brummer T., Hu Z., Dengjel J., Hackanson B., Schmid C., Holtick U., Scheid C., Spyridonidis A., Stölzel F., Ordemann R., Müller L.P., Sicre-de-Fontbrune F., Ihorst G., Kuball J., Ehlert J.E., Feger D., Wagner E.M., Cahn J.Y., Schnell J., Kuchenbauer F., Bunjes D., Chakraverty R., Richardson S., Gill S., Kröger N., Ayuk F., Vago L., Ciceri F., Müller A.M., Kondo T., Teshima T., Klaeger S., Kuster B., Kim D.D.H., Weisdorf D., van der Velden W., Dörfel D., Bethge W., Hilgendorf I., Hochhaus A., Andrieux G., Börries M., Busch H., Magenau J., Reddy P., Labopin M., Antin J.H., Henden A.S., Hill G.R., Kennedy G.A., Bar M., Sarma A., McLornan D., Mufti G., Oran B., Rezvani K., Shah O., Negrin R.S., Nagler A., Prinz M., Burchert A., Neubauer A., Beelen D., Mackensen A., von Bubnoff N., Herr W., Becher B., Socié G., Caligiuri M.A., Ruggiero E., Bonini C., Häcker G., Duyster J., Finke J., Pearce E., Blazar B.R. & Zeiser R.
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nat Med. 2018;24(4):526.
 
27. Maertens J.A., Girmenia C., Brüggemann R.J., Duarte R.F., Kibbler C.C., Ljungman P., Racil Z., Ribaud P., Slavin M.A., Cornely O.A., Peter Donnelly J., Cordonnier C., European Conference on Infections in Leukaemia (ECIL) a joint venture of the European Group for Blood and Marrow Transplantation (EBMT) the European Organization for Research and Treatment of Cancer (EORTC) the Immunocompromised Host Society (ICHS) and & European Conference on Infections in Leukaemia (ECIL) a joint venture of the European Group for Blood and Marrow Transplantation (EBMT) the European Organization for Research and Treatment of Cancer (EORTC) the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN)
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.
J Antimicrob Chemoth. 2018;73(12):3221-3230.
 
28. Greif P.A., Hartmann L., Vosberg S., Stief S.M., Mattes R., Hellmann I., Metzeler K.H., Herold T., Bamopoulos S.A., Kerbs P., Jurinovic V., Schumacher D., Pastore F., Bräundl K., Zellmeier E., Ksienzyk B., Konstandin N.P., Schneider S., Graf A., Krebs S., Blum H., Neumann M., Baldus C.D., Bohlander S.K., Wolf S., Görlich D., Berdel W.E., Wörmann B.J., Hiddemann W. & Spiekermann K.
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.
Clin Cancer Res. 2018;24(7):1716-1726.
 
29. Zajac M., Zaleska J., Dolnik A., Bullinger L. & Giannopoulos K.
Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.
Brit J Haematol. 2018;183(5):822-825.
 
30. Penter L., Dietze K., Bullinger L., Westermann J., Rahn H.P. & Hansmann L.
FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells.
Eur J Immunol. 2018;48(7):1248-1250.
 
31. Lengfelder E., Görlich D., Nowak D., Spiekermann K., Haferlach C., Krug U., Kreuzer K.A., Braess J., Schliemann C., Lindemann H.W., Horst H.A., Schiel X., Flasshove M., Hecht A., Schnittger S., Schneider S., Wörmann B., Hofmann W.K., Berdel W.E., Bormann E., Sauerland C., Büchner T., Hiddemann W. & German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Eur J Haematol. 2018;100(2):154-162.
 
32. Arends C.M., Galan-Sousa J., Hoyer K., Chan W., Jäger M., Yoshida K., Seemann R., Noerenberg D., Waldhueter N., Fleischer-Notter H., Christen F., Schmitt C.A., Dörken B., Pelzer U., Sinn M., Zemojtel T., Ogawa S., Märdian S., Schreiber A., Kunitz A., Krüger U., Bullinger L., Mylonas E., Frick M. & Damm F.
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.
Leukemia. 2018;32(9):1908-1919.
 
33. Spoerl S., Novotny A., Al-Batran S.E., Lordick F., Thuss-Patience P., Pauligk C., Haller B., Feith M. & Lorenzen S.
Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
Eur J Cancer. 2018;90:26-33.
 
34. Smyth E. & Thuss-Patience P.C.
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Oncol Res Treat. 2018;41(5):272-280.
 
35. Kiefer T., Krahl D., Osthoff K., Thuss-Patience P., Bunse J., Adam U., Jansen M.H., Ott R., Pfitzmann R., Pross M., Kohlmann T., Daeschlein G., Buhlert H., Völler H. & Hirt C.
Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric Junction.
Nutr Cancer. 2018;70(1):69-72.
 
36. Jacquelin S., Straube J., Cooper L., Vu T., Song A., Bywater M., Baxter E., Heidecker M., Wackrow B., Porter A., Ling V., Green J., Austin R., Kazakoff S., Waddell N., Hesson L.B., Pimanda J.E., Stegelmann F., Bullinger L., Döhner K., Rampal R.K., Heckl D., Hill G.R. & Lane S.W.
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Blood. 2018;132(26):2707-2721.
 
37. Thol F., Gabdoulline R., Liebich A., Klement P., Schiller J., Kandziora C., Hambach L., Stadler M., Koenecke C., Flintrop M., Pankratz M., Wichmann M., Neziri B., Büttner K., Heida B., Klesse S., Chaturvedi A., Kloos A., Göhring G., Schlegelberger B., Gaidzik V.I., Bullinger L., Fiedler W., Heim A., Hamwi I., Eder M., Krauter J., Schlenk R.F., Paschka P., Döhner K., Döhner H., Ganser A. & Heuser M.
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Blood. 2018;132(16):1703-1713.
 
38. Briest F., Grass I., Sedding D., Möbs M., Christen F., Benecke J., Fuchs K., Mende S., Kaemmerer D., Sänger J., Kunze A., Geisler C., Freitag H., Lewens F., Worpenberg L., Iwaszkiewicz S., Siegmund B., Walther W., Hummel M. & Grabowski P.
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Neuroendocrinology. 2018;107(1):1-23.
 
39. Hornung R., Jurinovic V., Batcha A.M.N., Bamopoulos S.A., Rothenberg-Thurley M., Amler S., Sauerland M.C., Berdel W.E., Wörmann B.J., Bohlander S.K., Braess J., Hiddemann W., Lehmann S., Mareschal S., Spiekermann K., Metzeler K.H., Herold T. & Boulesteix A.L.
Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.
Sci Rep. 2018;8(1):11293.
 
40. Schneider E., Staffas A., Röhner L., Malmberg E.D., Ashouri A., Krowiorz K., Pochert N., Miller C., Wei S.Y., Arabanian L., Buske C., Döhner H., Bullinger L., Fogelstrand L., Heuser M., Döhner K., Xiang P., Ruschmann J., Petriv O.I., Heravi-Moussavi A., Hansen C.L., Hirst M., Humphries R.K., Rouhi A., Palmqvist L. & Kuchenbauer F.
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.
Haematologica. 2018;103(2):246-255.
 
41. Ralla B., Busch J., Flörcken A., Westermann J., Zhao Z., Kilic E., Weickmann S., Jung M., Fendler A. & Jung K.
miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Cancers (Basel). 2018;10(9) 
 
42. Bender J., Bognar S., Camagna M., Donauer J.A.M., Eble J.W., Emig R., Fischer S., Jesser R., Keilholz L., Kokotek D.M.U., Neumann J., Nicklaus S., Oude Weernink R.R.Q.P.T., Stühn L.G., Wössner N., Krämer S.D., Schwenk P., Gensch N., Roth G. & Ulbrich M.H.
Multiplexed antibody detection from blood sera by immobilization of in vitro expressed antigens and label-free readout via imaging reflectometric interferometry (iRIf).
Biosens Bioelectron. 2018;115:97-103.
 
43. Frick M., Bettstetter M., Bertz S., Schwarz-Furlan S., Hartmann A., Richter T., Lenze D., Hummel M., Dreyling M., Lenz G. & Gaumann A.
Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
Leukemia Lymphoma. 2018;59(5):1260-1263.
 
44. Frech M., Teichler S., Feld C., Bouchard C., Berberich H., Sorg K., Mernberger M., Bullinger L., Bauer U.M. & Neubauer A.
MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.
Oncotarget. 2018;9(32):22423-22435.
 
45. L'Abbate A., Tolomeo D., Cifola I., Severgnini M., Turchiano A., Augello B., Squeo G., D'Addabbo P., Traversa D., Daniele G., Lonoce A., Pafundi M., Carella M., Palumbo O., Dolnik A., Muehlematter D., Schoumans J., Van Roy N., De Bellis G., Martinelli G., Merla G., Bullinger L., Haferlach C. & Storlazzi C.T.
MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
Leukemia. 2018;32(10):2152-2166.
 
46. Zschaeck S., Wust P., Melcher I., Nadobny J., Rau D., Striefler J., Pahl S., Flörcken A., Kunitz A. & Ghadjar P.
Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison.
Int J Hyperther. 2018;35(1):1-9.
 
47. Hoffmann F., Jaeger C., Bhattacharya A., Schmitt C.A. & Lisec J.
Nontargeted Identification of Tracer Incorporation in High-Resolution Mass Spectrometry.
Anal Chem. 2018;90(12):7253-7260.
 
48. Tsai J.J., Velardi E., Shono Y., Argyropoulos K.V., Holland A.M., Smith O.M., Yim N.L., Rao U.K., Kreines F.M., Lieberman S.R., Young L.F., Lazrak A., Youssef S., Fu Y.Y., Liu C., Lezcano C., Murphy G.F., Na I.K., Jenq R.R., Hanash A.M., Dudakov J.A. & van den Brink M.R.M.
Nrf2 regulates CD4+ T cell-induced acute graft-versus-host disease in mice.
Blood. 2018;132(26):2763-2774.
 
49. Kabrani E., Chu V.T., Tasouri E., Sommermann T., Baßler K., Ulas T., Zenz T., Bullinger L., Schultze J.L., Rajewsky K. & Sander S.
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.
Blood. 2018;132(25):2670-2683.
 
50. Müller A., Gillissen B., Richter A., Richter A., Chumduri C., Daniel P.T. & Scholz C.W.
Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Cell Death Dis. 2018;9(3):384.
 
51. Pelzer U.
Pankreaskarzinom – Therapiestandards und spezielle Situationen
Best Pract Onkol. 2018;13(5):-.
 
52. Quentin W., Geissler A., Wittenbecher F., Ballinger G., Berenson R., Bloor K., Forgione D.A., Köpf P., Kroneman M., Serden L., Suarez R., van Manen J.W. & Busse R.
Paying hospital specialists: Experiences and lessons from eight high-income countries.
Health Policy. 2018;122(5):473-484.
 
53. Shitara K., Özgüroğlu M., Bang Y.J., Di Bartolomeo M., Mandalà M., Ryu M.H., Fornaro L., Olesiński T., Caglevic C., Chung H.C., Muro K., Goekkurt E., Mansoor W., McDermott R.S., Shacham-Shmueli E., Chen X., Mayo C., Kang S.P., Ohtsu A., Fuchs C.S. & KEYNOTE-061 investigators
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Lancet. 2018;392(10142):123-133.
 
54. Hammer Q., Rückert T., Borst E.M., Dunst J., Haubner A., Durek P., Heinrich F., Gasparoni G., Babic M., Tomic A., Pietra G., Nienen M., Blau I.W., Hofmann J., Na I.K., Prinz I., Koenecke C., Hemmati P., Babel N., Arnold R., Walter J., Thurley K., Mashreghi M.F., Messerle M. & Romagnani C.
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells.
Nat Immunol. 2018;19(5):453-463.
 
55. Stahl M., Maderer A., Lordick F., Mihaljevic A.L., Kanzler S., Hoehler T., Thuss-Patience P., Mönig S., Kunzmann V., Schroll S., Sandermann A., Tannapfel A., Meyer H.J., Schuhmacher C., Wilke H., Moehler M. & Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Eur J Cancer. 2018;93:119-126.
 
56. Ostendorf B.N., Flenner E., Flörcken A. & Westermann J.
Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.
PLoS ONE. 2018;13(5):e0197823.
 
57. Vogel A., Kasper S., Bitzer M., Block A., Sinn M., Schulze-Bergkamen H., Moehler M., Pfarr N., Endris V., Goeppert B., Merx K., Schnoy E., Siveke J.T., Michl P., Waldschmidt D., Kuhlmann J., Geissler M., Kahl C., Evenkamp R., Schmidt T., Kuhlmann A., Weichert W. & Kubicka S.
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Eur J Cancer. 2018;92:11-19.
 
58. Mellinghoff S.C., Panse J., Alakel N., Behre G., Buchheidt D., Christopeit M., Hasenkamp J., Kiehl M., Koldehoff M., Krause S.W., Lehners N., von Lilienfeld-Toal M., Löhnert A.Y., Maschmeyer G., Teschner D., Ullmann A.J., Penack O., Ruhnke M., Mayer K., Ostermann H., Wolf H.H. & Cornely O.A.
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Ann Hematol. 2018;97(2):197-207.
 
59. Wais V., Kündgen L., Bohl S.R., von Harsdorf S., Schlenk R.F., Döhner K., Teleanu V., Bullinger L., Nguyen T.M., Drognitz K., Moulin J.C., Binnenhei M., Bentz M., Döhner H., Bunjes D., Kuchenbauer F. & Ringhoffer M.
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Bone Marrow Transpl. 2018;53(1):94-96.
 
60. Rudat S., Pfaus A., Cheng Y.Y., Holtmann J., Ellegast J.M., Bühler C., Marcantonio D.D., Martinez E., Göllner S., Wickenhauser C., Müller-Tidow C., Lutz C., Bullinger L., Milsom M.D., Sykes S.M., Fröhling S. & Scholl C.
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Leukemia. 2018;32(10):2189-2202.
 
61. Klein F., Berresheim F., Felsenstein M., Malinka T., Pelzer U., Denecke T., Pratschke J. & Bahra M.
Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival.
EJSO-Eur J Surg Onc. 2018;44(7):1094-1099.
 
62. Pelzer U., Wislocka L., Jühling A., Striefler J., Klein F., Roemmler-Zehrer J., Sinn M., Denecke T., Bahra M. & Riess H.
Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Eur J Cancer. 2018;100:85-93.
 
63. Milanovic M., Fan D.N.Y., Belenki D., Däbritz J.H.M., Zhao Z., Yu Y., Dörr J.R., Dimitrova L., Lenze D., Monteiro Barbosa I.A., Mendoza-Parra M.A., Kanashova T., Metzner M., Pardon K., Reimann M., Trumpp A., Dörken B., Zuber J., Gronemeyer H., Hummel M., Dittmar G., Lee S. & Schmitt C.A.
Senescence-associated reprogramming promotes cancer stemness.
Nature. 2018;553(7686):96-100.
 
64. Waidmann O., Pelzer U., Boeck S. & Waldschmidt D.T.
Sequence therapy in metastatic pancreatic cancer.
Z Gastroenterol. 2018;56(6):578-582.
 
65. Rachakonda S.P., Dai H., Penack O., Blau O., Blau I.W., Radujkovic A., Müller-Tidow C., Kumar R., Dreger P. & Luft T.
Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.
J Clin Oncol. 2018;36(8):789-800.
 
66. Mathew N.R., Baumgartner F., Braun L., O'Sullivan D., Thomas S., Waterhouse M., Müller T.A., Hanke K., Taromi S., Apostolova P., Illert A.L., Melchinger W., Duquesne S., Schmitt-Graeff A., Osswald L., Yan K.L., Weber A., Tugues S., Spath S., Pfeifer D., Follo M., Claus R., Lübbert M., Rummelt C., Bertz H., Wäsch R., Haag J., Schmidts A., Schultheiss M., Bettinger D., Thimme R., Ullrich E., Tanriver Y., Vuong G.L., Arnold R., Hemmati P., Wolf D., Ditschkowski M., Jilg C., Wilhelm K., Leiber C., Gerull S., Halter J., Lengerke C., Pabst T., Schroeder T., Kobbe G., Rösler W., Doostkam S., Meckel S., Stabla K., Metzelder S.K., Halbach S., Brummer T., Hu Z., Dengjel J., Hackanson B., Schmid C., Holtick U., Scheid C., Spyridonidis A., Stölzel F., Ordemann R., Müller L.P., Sicre-de-Fontbrune F., Ihorst G., Kuball J., Ehlert J.E., Feger D., Wagner E.M., Cahn J.Y., Schnell J., Kuchenbauer F., Bunjes D., Chakraverty R., Richardson S., Gill S., Kröger N., Ayuk F., Vago L., Ciceri F., Müller A.M., Kondo T., Teshima T., Klaeger S., Kuster B., Kim D.D.H., Weisdorf D., van der Velden W., Dörfel D., Bethge W., Hilgendorf I., Hochhaus A., Andrieux G., Börries M., Busch H., Magenau J., Reddy P., Labopin M., Antin J.H., Henden A.S., Hill G.R., Kennedy G.A., Bar M., Sarma A., McLornan D., Mufti G., Oran B., Rezvani K., Shah O., Negrin R.S., Nagler A., Prinz M., Burchert A., Neubauer A., Beelen D., Mackensen A., von Bubnoff N., Herr W., Becher B., Socié G., Caligiuri M.A., Ruggiero E., Bonini C., Häcker G., Duyster J., Finke J., Pearce E., Blazar B.R. & Zeiser R.
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nat Med. 2018;24(3):282-291.
 
67. Yu Y., Schleich K., Yue B., Ji S., Lohneis P., Kemper K., Silvis M.R., Qutob N., van Rooijen E., Werner-Klein M., Li L., Dhawan D., Meierjohann S., Reimann M., Elkahloun A., Treitschke S., Dörken B., Speck C., Mallette F.A., Zon L.I., Holmen S.L., Peeper D.S., Samuels Y., Schmitt C.A. & Lee S.
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
Cancer Cell. 2018;33(4):785.
 
68. Schleussner N., Merkel O., Costanza M., Liang H.C., Hummel F., Romagnani C., Durek P., Anagnostopoulos I., Hummel M., Jöhrens K., Niedobitek A., Griffin P.R., Piva R., Sczakiel H.L., Woessmann W., Damm-Welk C., Hinze C., Stoiber D., Gillissen B., Turner S.D., Kaergel E., von Hoff L., Grau M., Lenz G., Dörken B., Scheidereit C., Kenner L., Janz M. & Mathas S.
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Leukemia. 2018;32(9):1994-2007.
 
69. Tsuda M., Fukuda A., Roy N., Hiramatsu Y., Leonhardt L., Kakiuchi N., Hoyer K., Ogawa S., Goto N., Ikuta K., Kimura Y., Matsumoto Y., Takada Y., Yoshioka T., Maruno T., Yamaga Y., Kim G.E., Akiyama H., Ogawa S., Wright C.V., Saur D., Takaori K., Uemoto S., Hebrok M., Chiba T. & Seno H.
The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis.
J Clin Invest. 2018;128(8):3475-3489.
 
70. Mohr J., Dash B.P., Schnoeder T.M., Wolleschak D., Herzog C., Tubio Santamaria N., Weinert S., Godavarthy S., Zanetti C., Naumann M., Hartleben B., Huber T.B., Krause D.S., Kähne T., Bullinger L. & Heidel F.H.
The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Leukemia. 2018;32(5):1211-1221.
 
71. Herwest S., Albers C., Schmiester M., Salewsky B., Hopfenmüller W., Meyer A., Bertram L. & Demuth I.
The hSNM1B/Apollo variant rs11552449 is associated with cellular sensitivity towards mitomycin C and ionizing radiation.
DNA Repair. 2018;72:93-98.
 
72. Meyer C., Burmeister T., Gröger D., Tsaur G., Fechina L., Renneville A., Sutton R., Venn N.C., Emerenciano M., Pombo-de-Oliveira M.S., Barbieri Blunck C., Almeida Lopes B., Zuna J., Trka J., Ballerini P., Lapillonne H., De Braekeleer M., Cazzaniga G., Corral Abascal L., van der Velden V.H.J., Delabesse E., Park T.S., Oh S.H., Silva M.L.M., Lund-Aho T., Juvonen V., Moore A.S., Heidenreich O., Vormoor J., Zerkalenkova E., Olshanskaya Y., Bueno C., Menendez P., Teigler-Schlegel A., Zur Stadt U., Lentes J., Göhring G., Kustanovich A., Aleinikova O., Schäfer B.W., Kubetzko S., Madsen H.O., Gruhn B., Duarte X., Gameiro P., Lippert E., Bidet A., Cayuela J.M., Clappier E., Alonso C.N., Zwaan C.M., van den Heuvel-Eibrink M.M., Izraeli S., Trakhtenbrot L., Archer P., Hancock J., Möricke A., Alten J., Schrappe M., Stanulla M., Strehl S., Attarbaschi A., Dworzak M., Haas O.A., Panzer-Grümayer R., Sedék L., Szczepański T., Caye A., Suarez L., Cavé H. & Marschalek R.
The MLL recombinome of acute leukemias in 2017.
Leukemia. 2018;32(2):273-284.
 
73. Nickel K., Renovanz M., König J., Stöckelmaier L., Hickmann A.K., Nadji-Ohl M., Engelke J., Weimann E., Freudenstein D., Ganslandt O., Bullinger L., Wirtz C.R. & Coburger J.
The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.
Neurosurg Rev. 2018;41(1):207-219.
 
74. Andreou A., Knitter S., Klein F., Malinka T., Schmelzle M., Struecker B., Schmuck R.B., Noltsch A.R., Lee D., Pelzer U., Denecke T., Pratschke J. & Bahra M.
The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma.
Surg Oncol. 2018;27(4):688-694.
 
75. Milanovic M., Yu Y. & Schmitt C.A.
The Senescence-Stemness Alliance - A Cancer-Hijacked Regeneration Principle.
Trends Cell Biol. 2018;28(12):1049-1061.
 
76. Lohneis P., Sinn M., Klein F., Bischoff S., Striefler J.K., Wislocka L., Sinn B.V., Pelzer U., Oettle H., Riess H., Denkert C., Bläker H. & Jühling A.
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Brit J Cancer. 2018;118(11):1485-1491.
 
77. Gül-Klein S., Sinn M., Jurmeister P.S., Biebl M., Weiß S., Rau B., Bläker H., Pratschke J. & Aigner F.
Two patients with rare mixed adenoneuroendocrine carcinomas of the rectum.
SAGE Open Med Case Rep. 2018;6:2050313X18758816.
 
78. Maifrede S., Nieborowska-Skorska M., Sullivan-Reed K., Dasgupta Y., Podszywalow-Bartnicka P., Le B.V., Solecka M., Lian Z., Belyaeva E.A., Nersesyan A., Machnicki M.M., Toma M., Chatain N., Rydzanicz M., Zhao H., Jelinek J., Piwocka K., Sliwinski T., Stoklosa T., Ploski R., Fischer T., Sykes S.M., Koschmieder S., Bullinger L., Valent P., Wasik M.A., Huang J. & Skorski T.
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood. 2018;132(1):67-77.
 
79. Schmitt C.A.
UnSASPing Senescence: Unmasking Tumor Suppression?
Cancer Cell. 2018;34(1):6-8.
 
80. Gozdecka M., Meduri E., Mazan M., Tzelepis K., Dudek M., Knights A.J., Pardo M., Yu L., Choudhary J.S., Metzakopian E., Iyer V., Yun H., Park N., Varela I., Bautista R., Collord G., Dovey O., Garyfallos D.A., De Braekeleer E., Kondo S., Cooper J., Göttgens B., Bullinger L., Northcott P.A., Adams D., Vassiliou G.S. & Huntly B.J.P.
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Nat Genet. 2018;50(6):883-894.

Publikationen 2017

1. Thol F., Klesse S., Köhler L., Gabdoulline R., Kloos A., Liebich A., Wichmann M., Chaturvedi A., Fabisch J., Gaidzik V.I., Paschka P., Bullinger L., Bug G., Serve H., Göhring G., Schlegelberger B., Lübbert M., Kirchner H., Wattad M., Kraemer D., Hertenstein B., Heil G., Fiedler W., Krauter J., Schlenk R.F., Döhner K., Döhner H., Ganser A. & Heuser M.
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Leukemia. 2017;31(6):1286-1295.
 
2. Herold T., Metzeler K.H., Vosberg S., Hartmann L., Jurinovic V., Opatz S., Konstandin N.P., Schneider S., Zellmeier E., Ksienzyk B., Graf A., Krebs S., Blum H., Cristina Sauerland M., Büchner T., Berdel W.E., Wörmann B.J., Mansmann U., Hiddemann W., Bohlander S.K., Spiekermann K. & Greif P.A.
Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Gene Chromosome Canc. 2017;56(1):75-86.
 
3. Greiner J., Hofmann S., Schmitt M., Götz M., Wiesneth M., Schrezenmeier H., Bunjes D., Döhner H. & Bullinger L.
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
Haematologica. 2017;102(12):e499-e501.
 
4. Zajac M., Dolnik A., Stasiak G., Zaleska J., Kielbus M., Czapinski J., Schunn M., Correa S.C., Glodkowska-Mrowka E., Sundaram R.C., Jankowska-Lecka O., Schlenk R.F., Döhner H., Döhner K., Stepulak A., Bullinger L. & Giannopoulos K.
Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.
Oncotarget. 2017;8(56):95163-95175.
 
5. Gillissen B., Richter A., Richter A., Preissner R., Schulze-Osthoff K., Essmann F. & Daniel P.T.
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
J Biol Chem. 2017;292(16):6478-6492.
 
6. Raffel S., Falcone M., Kneisel N., Hansson J., Wang W., Lutz C., Bullinger L., Poschet G., Nonnenmacher Y., Barnert A., Bahr C., Zeisberger P., Przybylla A., Sohn M., Tönjes M., Erez A., Adler L., Jensen P., Scholl C., Fröhling S., Cocciardi S., Wuchter P., Thiede C., Flörcken A., Westermann J., Ehninger G., Lichter P., Hiller K., Hell R., Herrmann C., Ho A.D., Krijgsveld J., Radlwimmer B. & Trumpp A.
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Nature. 2017;551(7680):384-388.
 
7. Wörmann B.
Breast cancer: basics, screening, diagnostics and treatment.
Med Monatsschr Pharm. 2017;40(2):55-64.
 
8. Qu Y., Siggens L., Cordeddu L., Gaidzik V.I., Karlsson K., Bullinger L., Döhner K., Ekwall K., Lehmann S. & Lennartsson A.
Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Blood. 2017;129(7):e13-e25.
 
9. Mengwasser J., Babes L., Cordes S., Mertlitz S., Riesner K., Shi Y., McGearey A., Kalupa M., Reinheckel T. & Penack O.
Cathepsin E Deficiency Ameliorates Graft-versus-Host Disease and Modifies Dendritic Cell Motility.
Front Immunol. 2017;8:203.
 
10. Kayser S., Krzykalla J., Elliott M.A., Norsworthy K., Gonzales P., Hills R.K., Baer M.R., Ráčil Z., Mayer J., Novak J., Žák P., Szotkowski T., Grimwade D., Russell N.H., Walter R.B., Estey E.H., Westermann J., Görner M., Benner A., Krämer A., Smith B.D., Burnett A.K., Thiede C., Röllig C., Ho A.D., Ehninger G., Schlenk R.F., Tallman M.S., Levis M.J. & Platzbecker U.
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
Leukemia. 2017;31(11):2347-2354.
 
11. Hirsch S., Blätte T.J., Grasedieck S., Cocciardi S., Rouhi A., Jongen-Lavrencic M., Paschka P., Krönke J., Gaidzik V.I., Döhner H., Schlenk R.F., Kuchenbauer F., Döhner K., Dolnik A. & Bullinger L.
Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.
Haematologica. 2017;102(12):2039-2047.
 
12. Ihlow J. & Westermann J.
[Clinical Autopsies from the Perspective of a Hematologist/Oncologist].
Pathologe. 2017;38(5):380-383.
 
13. Hansmann L., Han A., Penter L., Liedtke M. & Davis M.M.
Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.
Cancer Immunol Res. 2017;5(9):744-754.
 
14. Jaeger C., Méret M., Schmitt C.A. & Lisec J.
Compound annotation in liquid chromatography/high-resolution mass spectrometry based metabolomics: robust adduct ion determination as a prerequisite to structure prediction in electrospray ionization mass spectra.
Rapid Commun Mass Sp. 2017;31(15):1261-1266.
 
15. Sinn M., Bahra M., Liersch T., Gellert K., Messmann H., Bechstein W., Waldschmidt D., Jacobasch L., Wilhelm M., Rau B.M., Grützmann R., Weinmann A., Maschmeyer G., Pelzer U., Stieler J.M., Striefler J.K., Ghadimi M., Bischoff S., Dörken B., Oettle H. & Riess H.
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
J Clin Oncol. 2017;35(29):3330-3337.
 
16. Lohneis P., Sinn M., Bischoff S., Jühling A., Pelzer U., Wislocka L., Bahra M., Sinn B.V., Denkert C., Oettle H., Bläker H., Riess H., Jöhrens K. & Striefler J.K.
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Eur J Cancer. 2017;83:290-301.
 
17. Fan D.N.Y. & Schmitt C.A.
Detecting Markers of Therapy-Induced Senescence in Cancer Cells.
Methods Mol Biol. 2017;1534:41-52.
 
18. Heinz W.J., Buchheidt D., Christopeit M., von Lilienfeld-Toal M., Cornely O.A., Einsele H., Karthaus M., Link H., Mahlberg R., Neumann S., Ostermann H., Penack O., Ruhnke M., Sandherr M., Schiel X., Vehreschild J.J., Weissinger F. & Maschmeyer G.
Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
Ann Hematol. 2017;96(11):1775-1792.
 
19. Zschaeck S., Blümke B., Wust P., Kaul D., Bahra M., Riess H., Klein F., Sinn M., Pelzer U., Budach V. & Ghadjar P.
Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.
PLoS ONE. 2017;12(10):e0186341.
 
20. Luft T., Benner A., Jodele S., Dandoy C.E., Storb R., Gooley T., Sandmaier B.M., Becker N., Radujkovic A., Dreger P. & Penack O.
EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
Lancet Haematol. 2017;4(9):e414-e423.
 
21. Young E., Noerenberg D., Mansouri L., Ljungström V., Frick M., Sutton L.A., Blakemore S.J., Galan-Sousa J., Plevova K., Baliakas P., Rossi D., Clifford R., Roos-Weil D., Navrkalova V., Dörken B., Schmitt C.A., Smedby K.E., Juliusson G., Giacopelli B., Blachly J.S., Belessi C., Panagiotidis P., Chiorazzi N., Davi F., Langerak A.W., Oscier D., Schuh A., Gaidano G., Ghia P., Xu W., Fan L., Bernard O.A., Nguyen-Khac F., Rassenti L., Li J., Kipps T.J., Stamatopoulos K., Pospisilova S., Zenz T., Oakes C.C., Strefford J.C., Rosenquist R. & Damm F.
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Leukemia. 2017;31(7):1547-1554.
 
22. Henke A., Thuss-Patience P., Behzadi A. & Henke O.
End-of-life care for immigrants in Germany. An epidemiological appraisal of Berlin.
PLoS ONE. 2017;12(8):e0182033.
 
23. Mir E., Palomo M., Rovira M., Pereira A., Escolar G., Penack O., Holler E., Carreras E. & Diaz-Ricart M.
Endothelial damage is aggravated in acute GvHD and could predict its development.
Bone Marrow Transpl. 2017;52(9):1317-1325.
 
24. Nagel G., Weber D., Fromm E., Erhardt S., Lübbert M., Fiedler W., Kindler T., Krauter J., Brossart P., Kündgen A., Salih H.R., Westermann J., Wulf G., Hertenstein B., Wattad M., Götze K., Kraemer D., Heinicke T., Girschikofsky M., Derigs H.G., Horst H.A., Rudolph C., Heuser M., Göhring G., Teleanu V., Bullinger L., Thol F., Gaidzik V.I., Paschka P., Döhner K., Ganser A., Döhner H., Schlenk R.F. & German-Austrian AML Study Group (AMLSG)
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
Ann Hematol. 2017;96(12):1993-2003.
 
25. Hiller J.K., Schmoor C., Gaidzik V.I., Schmidt-Salzmann C., Yalcin A., Abdelkarim M., Blagitko-Dorfs N., Döhner K., Bullinger L., Duyster J., Lübbert M. & Hackanson B.
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Ann Hematol. 2017;96(4):559-565.
 
26. Cosson A., Chapiro E., Bougacha N., Lambert J., Herbi L., Cung H.A., Algrin C., Keren B., Damm F., Gabillaud C., Brunelle-Navas M.N., Davi F., Merle-Béral H., Le Garff-Tavernier M., Roos-Weil D., Choquet S., Uzunov M., Morel V., Leblond V., Maloum K., Lepretre S., Feugier P., Lesty C., Lejeune J., Sutton L., Landesman Y., Susin S.A. & Nguyen-Khac F.
Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.
Leukemia. 2017;31(7):1625-1629.
 
27. Bohl S.R., Dolnik A., Jensen T., Lang K.M., Hackanson B., Gaidzik V.I., Paschka P., Knudsen S., Döhner K., Döhner H., Claus R., Lübbert M. & Bullinger L.
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Leukemia Lymphoma. 2017;58(9):1-4.
 
28. Nieborowska-Skorska M., Sullivan K., Dasgupta Y., Podszywalow-Bartnicka P., Hoser G., Maifrede S., Martinez E., Di Marcantonio D., Bolton-Gillespie E., Cramer-Morales K., Lee J., Li M., Slupianek A., Gritsyuk D., Cerny-Reiterer S., Seferynska I., Stoklosa T., Bullinger L., Zhao H., Gorbunova V., Piwocka K., Valent P., Civin C.I., Muschen M., Dick J.E., Wang J.C., Bhatia S., Bhatia R., Eppert K., Minden M.D., Sykes S.M. & Skorski T.
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
J Clin Invest. 2017;127(6):2392-2406.
 
29. Bullinger L., Döhner K. & Döhner H.
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
J Clin Oncol. 2017;35(9):934-946.
 
30. Duwe G., Knitter S., Pesthy S., Beierle A.S., Bahra M., Schmelzle M., Schmuck R.B., Lohneis P., Raschzok N., Öllinger R., Sinn M., Struecker B., Sauer I.M., Pratschke J. & Andreou A.
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
EJSO-Eur J Surg Onc. 2017;43(9):1668-1681.
 
31. Lordick F., Al-Batran S.E., Dietel M., Gaiser T., Hofheinz R.D., Kirchner T., Kreipe H.H., Lorenzen S., Möhler M., Quaas A., Röcken C., Rüschoff J., Tannapfel A., Thuss-Patience P. & Baretton G.
HER2 testing in gastric cancer: results of a German expert meeting.
J Cancer Res Clin. 2017;143(5):835-841.
 
32. Thiel V.N., Giaimo B.D., Schwarz P., Soller K., Vas V., Bartkuhn M., Blätte T.J., Döhner K., Bullinger L., Borggrefe T., Geiger H. & Oswald F.
Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Leukemia. 2017;31(11):2491-2502.
 
33. Eldfors S., Kuusanmäki H., Kontro M., Majumder M.M., Parsons A., Edgren H., Pemovska T., Kallioniemi O., Wennerberg K., Gökbuget N., Burmeister T., Porkka K. & Heckman C.A.
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Leukemia. 2017;31(1):51-57.
 
34. Kassubek R., Bullinger L., Kassubek J., Dreyhaupt J., Ludolph A.C., Althaus K. & Lewerenz J.
Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.
J Neurol. 2017;264(4):781-791.
 
35. Krönke J., Kuchenbauer F., Kull M., Teleanu V., Bullinger L., Bunjes D., Greiner A., Kolmus S., Köpff S., Schreder M., Mügge L.O., Straka C., Engelhardt M., Döhner H., Einsele H., Bassermann F., Bargou R., Knop S. & Langer C.
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Leukemia. 2017;31(6):1363-1367.
 
36. Flörcken A., Johannsen M., Nguyen-Hoai T., Gerhardt A., Miller K., Dörken B., Pezzutto A., Westermann J. & Jöhrens K.
Immunomodulatory molecules in renal cell cancer
Int J Clin Exp Patho. 2017;10:1443-1454.
 
37. Flörcken A., Johannsen M., Nguyen-Hoai T., Wagner A.C., Gerhardt A., Miller K., Dörken B., Pezzutto A., Westermann J. & Joehrens K.
Immunomodulatory molecules in renal cell cancer: CD80 and CD86 are expressed on tumor cells.
Int J Clin Exp Patho. 2017;10(2):1443-1554.
 
38. Andreou A., Klein F., Schmuck R.B., Lee D., Sinn M., Denecke T., Pratschke J. & Bahra M.
Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patients Undergoing Salvage Pancreatectomy.
Anticancer Res. 2017;37(9):5269-5275.
 
39. Jahn N., Agrawal M., Bullinger L., Weber D., Corbacioglu A., Gaidzik V.I., Schmalbrock L., Thol F., Heuser M., Krauter J., Göhring G., Kündgen A., Fiedler W., Wattad M., Held G., Köhne C.H., Horst H.A., Lübbert M., Ganser A., Schlenk R.F., Döhner H., Döhner K. & Paschka P.
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Leukemia. 2017;31(4):1012-1015.
 
40. Freitag H., Christen F., Lewens F., Grass I., Briest F., Iwaszkiewicz S., Siegmund B. & Grabowski P.
Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Neuroendocrinology. 2017;105(1):90-104.
 
41. Riesner K., Shi Y., Jacobi A., Kräter M., Kalupa M., McGearey A., Mertlitz S., Cordes S., Schrezenmeier J.F., Mengwasser J., Westphal S., Perez-Hernandez D., Schmitt C., Dittmar G., Guck J. & Penack O.
Initiation of acute graft-versus-host disease by angiogenesis.
Blood. 2017;129(14):2021-2032.
 
42. Langer T., Grabow D., Steinmann D., Wörmann B. & Calaminus G.
Late Effects and Long-Term Follow-Up after Cancer in Childhood.
Oncol Res Treat. 2017;40(12):746-750.
 
43. Bröckelmann P.J., Goergen H., Kohnhorst C., von Tresckow B., Moccia A., Markova J., Meissner J., Kerkhoff A., Ludwig W.D., Fuchs M., Borchmann P. & Engert A.
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
J Clin Oncol. 2017;35(13):1444-1450.
 
44. Kühl J.S., Suarez F., Gillett G.T., Hemmati P.G., Snowden J.A., Stadler M., Vuong G.L., Aubourg P., Köhler W. & Arnold R.
Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy.
Brain. 2017;140(4):953-966.
 
45. Gökbuget N., Zugmaier G., Klinger M., Kufer P., Stelljes M., Viardot A., Horst H.A., Neumann S., Brüggemann M., Ottmann O.G., Burmeister T., Wessiepe D., Topp M.S. & Bargou R.
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Haematologica. 2017;102(4):e132-e135.
 
46. Kobitzsch B., Gökbuget N., Schwartz S., Reinhardt R., Brüggemann M., Viardot A., Wäsch R., Starck M., Thiel E., Hoelzer D. & Burmeister T.
Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL -negative acute lymphoblastic leukemia.
Haematologica. 2017;102(10):1739-1747.
 
47. Mertlitz S., Shi Y., Kalupa M., Grötzinger C., Mengwasser J., Riesner K., Cordes S., Elezkurtaj S. & Penack O.
Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD.
Blood. 2017;129(13):1865-1875.
 
48. Radhakrishnan H., Ilm K., Walther W., Shirasawa S., Sasazuki T., Daniel P.T., Gillissen B. & Stein U.
MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers.
Cancer Lett. 2017;403:231-245.
 
49. Mahlberg R., Lorenzen S., Thuss-Patience P., Heinemann V., Pfeiffer P. & Möhler M.
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Chemotherapy. 2017;62(1):62-70.
 
50. Schuler P.J., Laban S., Doescher J., Bullinger L. & Hoffmann T.K.
Novel Treatment Options in Head and Neck Cancer.
Oncol Res Treat. 2017;40(6):342-346.
 
51. Hess M., Lenz S., Blätte T.J., Bullinger L. & Binder H.
Partitioned learning of deep Boltzmann machines for SNP data.
Bioinformatics. 2017;33(20):3173-3180.
 
52. Du J., Neuenschwander M., Yu Y., Däbritz J.H.M., Neuendorff N.R., Schleich K., Bittner A., Milanovic M., Beuster G., Radetzki S., Specker E., Reimann M., Rosenbauer F., Mathas S., Lohneis P., Hummel M., Dörken B., von Kries J.P., Lee S. & Schmitt C.A.
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma.
Blood. 2017;129(1):71-81.
 
53. Gerstung M., Papaemmanuil E., Martincorena I., Bullinger L., Gaidzik V.I., Paschka P., Heuser M., Thol F., Bolli N., Ganly P., Ganser A., McDermott U., Döhner K., Schlenk R.F., Döhner H. & Campbell P.J.
Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Nat Genet. 2017;49(3):332-340.
 
54. Hemmati P.G., Vuong L.G., Terwey T.H., Jehn C.F., le Coutre P., Penack O., Na I.K., Dörken B. & Arnold R.
Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
Eur J Haematol. 2017;98(2):160-168.
 
55. Rouhi A., Miller C., Grasedieck S., Reinhart S., Stolze B., Döhner H., Kuchenbauer F., Bullinger L., Fröhling S. & Scholl C.
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Oncotarget. 2017;8(5):7678-7690.
 
56. Taromi S., Lewens F., Arsenic R., Sedding D., Sänger J., Kunze A., Möbs M., Benecke J., Freitag H., Christen F., Kaemmerer D., Lupp A., Heilmann M., Lammert H., Schneider C.P., Richter K., Hummel M., Siegmund B., Burger M., Briest F. & Grabowski P.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Oncotarget. 2017;8(57):97061-97078.
 
57. Herzig J.K., Bullinger L., Tasdogan A., Zimmermann P., Schlegel M., Teleanu V., Weber D., Rücker F.G., Paschka P., Dolnik A., Schneider E., Kuchenbauer F., Heidel F.H., Buske C., Döhner H., Döhner K. & Gaidzik V.I.
Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.
Oncotarget. 2017;8(56):95038-95053.
 
58. Pelzer U., Blanc J.F., Melisi D., Cubillo A., Von Hoff D.D., Wang-Gillam A., Chen L.T., Siveke J.T., Wan Y., Solem C.T., Botteman M.F., Yang Y., de Jong F.A. & Hubner R.A.
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Brit J Cancer. 2017;116(10):1247-1253.
 
59. Hoffmann T.K., Schuler P.J., Laban S., Grässlin R., Beer M., Beer A.J., Friebe-Hoffmann U., Bullinger L., Möller P. & Wiegel T.
Response Evaluation in Head and Neck Oncology: Definition and Prediction.
ORL J Oto-Rhino-Lary. 2017;79(1-2):14-23.
 
60. Schweitzer N., Fischer M., Kirstein M.M., Berhane S., Kottas M., Sinn M., Gonzalez-Carmona M.A., Balta Z., Weismüller T.J., Strassburg C.P., Reineke-Plaaß T., Bektas H., Manns M.P., Johnson P., Weinmann A. & Vogel A.
Risk estimation for biliary tract cancer: Development and validation of a prognostic score.
Liver Int. 2017;37(12):1852-1860.
 
61. Delestré L., Cui H., Esposito M., Quiveron C., Mylonas E., Penard-Lacronique V., Bischof O. & Guillouf C.
Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.
Haematologica. 2017;102(11):1850-1860.
 
62. Thuss-Patience P., Vecchione L. & Keilholz U.
Should cT2 esophageal cancer get neoadjuvant treatment before surgery?
J Thorac Dis. 2017;9(9):2819-2823.
 
63. Schmiester M. & Demuth I.
SNM1B/Apollo in the DNA damage response and telomere maintenance.
Oncotarget. 2017;8(29):48398-48409.
 
64. Sinn M., Sinn B.V., Striefler J.K., Lindner J.L., Stieler J.M., Lohneis P., Bischoff S., Bläker H., Pelzer U., Bahra M., Dietel M., Dörken B., Oettle H., Riess H. & Denkert C.
SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study.
Ann Oncol. 2017;28(11):2900.
 
65. Freimund L., Westermann J., wernecke K.D., Ebert A.D. & David M.
Subjektive versus objektive Anämie bei Myompatientinnen
Frauenarzt. 2017;58:382-386.
 
66. Jordan K., Feyer P., Höller U., Link H., Wörmann B. & Jahn F.
Supportive Treatments for Patients with Cancer.
Dtsch Arztebl Int. 2017;114(27-28):481-487.
 
67. Westphal S., McGeary A., Rudloff S., Wilke A. & Penack O.
The Green Tea Catechin Epigallocatechin Gallate Ameliorates Graft-versus-Host Disease.
PLoS ONE. 2017;12(1):e0169630.
 
68. Both A., Krauter J., Damm F., Thol F., Göhring G., Heuser M., Ottmann O., Lübbert M., Wattad M., Kanz L., Schlimok G., Raghavachar A., Fiedler W., Kirchner H., Brugger W., Schlegelberger B., Heil G., Ganser A. & Wagner K.
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Ann Hematol. 2017;96(6):895-904.
 
69. El-Athman R., Genov N.N., Mazuch J., Zhang K., Yu Y., Fuhr L., Abreu M., Li Y., Wallach T., Kramer A., Schmitt C.A. & Relógio A.
The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity.
PLoS Biol. 2017;15(12):e2002940.
 
70. Yalcin A., Kovarbasic M., Wehrle J., Claus R., Becker H., Abdelkarim M., Gaidzik V.I., Schmidts A., Wäsch R., Pahl H.L., Döhner K., Bullinger L., Duyster J., Lübbert M. & Hackanson B.
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Exp Hematol. 2017;55:76-85.e3.
 
71. Stache V., Verlaat L., Gätjen M., Heinig K., Westermann J., Rehm A. & Höpken U.E.
The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.
Oncoimmunology. 2017;6(6):e1323155.
 
72. Wörmann B.
The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.
Dtsch Arztebl Int. 2017;114(1-02):9-10.
 
73. Rademacher S., Seehofer D., Eurich D., Schoening W., Neuhaus R., Oellinger R., Denecke T., Pascher A., Schott E., Sinn M., Neuhaus P. & Pratschke J.
The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
Liver Transplant. 2017;23(11):1404-1414.
 
74. Stöckelmaier L., Renovanz M., König J., Nickel K., Hickmann A.K., Mayer-Steinacker R., Nadji-Ohl M., Ganslandt O., Bullinger L., Wirtz C.R. & Coburger J.
Therapy for Recurrent High-Grade Gliomas: Results of a Prospective Multicenter Study on Health-Related Quality of Life.
World Neurosurg. 2017;102:383-399.
 
75. Thuss-Patience P.C., Shah M.A., Ohtsu A., Van Cutsem E., Ajani J.A., Castro H., Mansoor W., Chung H.C., Bodoky G., Shitara K., Phillips G.D.L., van der Horst T., Harle-Yge M.L., Althaus B.L. & Kang Y.K.
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Lancet Oncol. 2017;18(5):640-653.
 
76. Röhrig F., Vorlová S., Hoffmann H., Wartenberg M., Escorcia F.E., Keller S., Tenspolde M., Weigand I., Gätzner S., Manova K., Penack O., Scheinberg D.A., Rosenwald A., Ergün S., Granot Z. & Henke E.
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.
Oncogene. 2017;36(1):1-12.